CO5261584A1 - Anticuerpos para il-1 humana - Google Patents

Anticuerpos para il-1 humana

Info

Publication number
CO5261584A1
CO5261584A1 CO01003434A CO01003434A CO5261584A1 CO 5261584 A1 CO5261584 A1 CO 5261584A1 CO 01003434 A CO01003434 A CO 01003434A CO 01003434 A CO01003434 A CO 01003434A CO 5261584 A1 CO5261584 A1 CO 5261584A1
Authority
CO
Colombia
Prior art keywords
human
antibody
antibodies
mfi
jpeg
Prior art date
Application number
CO01003434A
Other languages
English (en)
Spanish (es)
Inventor
Hermann Gram
Padova Franco E Di
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5261584(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5261584A1 publication Critical patent/CO5261584A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
CO01003434A 2000-01-21 2001-01-18 Anticuerpos para il-1 humana CO5261584A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds

Publications (1)

Publication Number Publication Date
CO5261584A1 true CO5261584A1 (es) 2003-03-31

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01003434A CO5261584A1 (es) 2000-01-21 2001-01-18 Anticuerpos para il-1 humana

Country Status (33)

Country Link
US (4) US20030124617A1 (enExample)
EP (1) EP1248804B2 (enExample)
JP (2) JP3978338B2 (enExample)
KR (1) KR100697126B1 (enExample)
CN (1) CN1395581B (enExample)
AR (1) AR027253A1 (enExample)
AT (1) ATE346868T1 (enExample)
AU (1) AU772949B2 (enExample)
BR (1) BR0107661A (enExample)
CA (1) CA2396212C (enExample)
CO (1) CO5261584A1 (enExample)
CY (1) CY1107989T1 (enExample)
CZ (1) CZ302738B6 (enExample)
DE (1) DE60124863T3 (enExample)
DK (1) DK1248804T4 (enExample)
ES (1) ES2274865T5 (enExample)
GB (1) GB0001448D0 (enExample)
HK (1) HK1050013A1 (enExample)
HU (1) HUP0204156A3 (enExample)
IL (2) IL150551A0 (enExample)
MX (1) MXPA02007091A (enExample)
MY (1) MY155269A (enExample)
NO (1) NO329816B1 (enExample)
NZ (1) NZ519936A (enExample)
PE (1) PE20011219A1 (enExample)
PL (1) PL207642B1 (enExample)
PT (1) PT1248804E (enExample)
RU (1) RU2264413C2 (enExample)
SI (1) SI1248804T2 (enExample)
SK (1) SK288054B6 (enExample)
TR (1) TR200201780T2 (enExample)
WO (1) WO2001053353A2 (enExample)
ZA (1) ZA200205659B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
MXPA02012867A (es) 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
KR20040077889A (ko) * 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20060094056A1 (en) * 2003-09-15 2006-05-04 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose treat, and evaluate inflammatory and autoimmune diseases
EP2857418B1 (en) 2004-02-06 2017-07-26 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
ES2569917T3 (es) * 2005-06-21 2016-05-13 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
EP2848258B1 (en) * 2005-10-26 2017-12-13 Novartis AG Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
RS55963B1 (sr) * 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
AU2007238677B2 (en) * 2006-04-14 2011-03-10 Novartis Ag Use of IL-I antibodies for treating ophthalmic disorders
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
EP2114443A4 (en) * 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
EP3406263A1 (en) * 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
DK2391650T3 (en) * 2007-12-20 2015-01-12 Xoma Us Llc Methods of treating gout
CA2727171A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
CA2735939A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
WO2011140522A1 (en) * 2010-05-07 2011-11-10 Xoma Technology Ltd. METHODS FOR THE TREATMENT OF IL-1β RELATED CONDITIONS
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
KR102306967B1 (ko) 2010-08-02 2021-10-01 리제너론 파아마슈티컬스, 인크. Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
EP2614085B1 (en) 2010-09-10 2016-04-20 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
LT2738259T (lt) 2011-02-25 2020-03-10 Regeneron Pharmaceuticals, Inc. Adam6 pelės
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
JP6320300B2 (ja) 2011-12-19 2018-05-09 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 座瘡を治療するための方法
PT3527070T (pt) 2011-12-20 2025-12-19 Regeneron Pharma Murganhos de cadeia leve humanizada
PT2814843T (pt) 2012-02-13 2020-06-18 Agency Science Tech & Res Anticorpos monoclonais humanos neutralizantes de il-b
EP3912464A1 (en) 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
ES3064335T3 (en) 2018-03-05 2026-04-24 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
CN110818793A (zh) 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
MX2021005905A (es) 2018-11-20 2021-06-23 Janssen Biotech Inc Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MX2022014430A (es) 2020-05-21 2023-02-22 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
CN116063489B (zh) * 2022-10-21 2026-01-30 杭州靶向食品科技有限公司 一种治疗痛风的单克隆抗体及其相应的组合物
CN121511262A (zh) 2023-06-28 2026-02-10 北京哲源科技有限责任公司 靶向pd-l1和il-1的双特异性抗体及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1248804B1 (en) 2006-11-29
GB0001448D0 (en) 2000-03-08
US20030124617A1 (en) 2003-07-03
WO2001053353A2 (en) 2001-07-26
MXPA02007091A (es) 2002-12-13
AR027253A1 (es) 2003-03-19
KR20020073178A (ko) 2002-09-19
EP1248804A2 (en) 2002-10-16
ATE346868T1 (de) 2006-12-15
RU2002121649A (ru) 2004-03-10
NO329816B1 (no) 2010-12-27
NZ519936A (en) 2004-02-27
IL150551A0 (en) 2003-02-12
NO20023266D0 (no) 2002-07-05
CA2396212C (en) 2013-04-02
EP1248804B2 (en) 2009-12-02
HUP0204156A2 (hu) 2003-03-28
BR0107661A (pt) 2002-11-19
US7491392B2 (en) 2009-02-17
JP2007097598A (ja) 2007-04-19
DE60124863T2 (de) 2007-04-26
PL356297A1 (en) 2004-06-28
CZ20022531A3 (cs) 2002-10-16
US20090232803A1 (en) 2009-09-17
DK1248804T3 (da) 2007-02-26
AU772949B2 (en) 2004-05-13
CA2396212A1 (en) 2001-07-26
SK288054B6 (sk) 2013-03-01
IL150551A (en) 2010-11-30
ES2274865T5 (es) 2010-04-19
SI1248804T2 (sl) 2010-04-30
DK1248804T4 (da) 2010-04-06
SK10352002A3 (sk) 2003-03-04
PT1248804E (pt) 2007-02-28
KR100697126B1 (ko) 2007-03-20
CY1107989T1 (el) 2013-09-04
SI1248804T1 (sl) 2007-06-30
US20060251660A1 (en) 2006-11-09
MY155269A (en) 2015-09-30
HUP0204156A3 (en) 2005-09-28
RU2264413C2 (ru) 2005-11-20
TR200201780T2 (tr) 2003-01-21
JP3978338B2 (ja) 2007-09-19
US20110182894A1 (en) 2011-07-28
ZA200205659B (en) 2003-12-31
JP2003520595A (ja) 2003-07-08
AU3369701A (en) 2001-07-31
DE60124863T3 (de) 2010-05-20
PL207642B1 (pl) 2011-01-31
NO20023266L (no) 2002-08-28
PE20011219A1 (es) 2001-12-17
WO2001053353A3 (en) 2002-04-04
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
HK1050013A1 (zh) 2003-06-06
ES2274865T3 (es) 2007-06-01
CN1395581B (zh) 2010-10-13
CN1395581A (zh) 2003-02-05

Similar Documents

Publication Publication Date Title
AR027253A1 (es) Anticuerpos para il-1beta humana
BR0113420A (pt) Anticorpos para il-1beta humano
TNSN07034A1 (en) Il - 17 antagonistic antibodies
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
IL195085A0 (en) Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody
EA200400526A1 (ru) Агенты, специфически связывающиеся с человеческим ангиопоэтином-2
MY207353A (en) Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
CY1114851T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων
EP2305716A3 (en) Antibodies directed to gpnmb and uses thereof
HRP20010551B1 (hr) Humana monoklonalna antitijela za ctla-4
CY1111845T1 (el) Μορια δεσμευομενα me cd20
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
MXPA05007853A (es) Antagonistas de il-1 beta humana.
NO20061070L (no) Antistoffer mot parathyoidhormon (PTH) og anvendelser derav
EA201070888A1 (ru) Антитела и их производные
ATE548386T1 (de) Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
BR0116686A (pt) Anticorpos anti-cd28 silenciados e uso dos mesmos
AR052889A1 (es) Anticuerpos contra interleuquina-1 beta
TW200635946A (en) Binding proteins specific for human matriptase
UA108734C2 (uk) Моноклональне антитіло, що специфічно зв'язується з протеїнконвертазою субтілізин кексин типу 9 (pcsk9)
WO2008141511A8 (fr) ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION

Legal Events

Date Code Title Description
FG Application granted